AIM
NBIX icon

AXA Investment Managers’s Neurocrine Biosciences NBIX Stock Holding History

AXA Investment Managers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$45.5M Buy
+323,896
New +$43.9M 0.12% 151

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AXA Investment Managers's NBIX Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 323,896 shares worth $45.5M. The stake represents 0.12% of the portfolio and ranks #151 among its holdings.

649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • AXA Investment Managers held 323,896 shares of Neurocrine Biosciences worth $45.5M as of Q3 2025.
  • Neurocrine Biosciences was a new AXA Investment Managers position in Q3 2025.
  • Neurocrine Biosciences made up 0.12% of AXA Investment Managers's portfolio in Q3 2025, its #151 holding.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.